文献速递泌尿系结石

肾结石的经济负担与疾病特异性经济毒性的预测因素

The Financial Burden of Nephrolithiasis and Predictors of Disease-specific Financial Toxicity.
PubMed 文献 · Urology · 2022-10-15

该研究通过经过验证的经济毒性问卷和疾病特异性健康相关生活质量问卷,描述美国成人肾结石患者结石相关经济毒性。研究对来自全国志愿者登记库(ResearchMatch)的成人肾结石患者进行横断面调查,评估结石事件史、医疗费用、疾病特异性生活质量(WISQOL)和11条目结石相关经济毒性(COST-11评分)。结果显示,942份回复中COST-11评分中位数为29(IQR 21-38),24.7%(N=233)符合疾病特异性经济毒性标准;经济毒性患者自付费用更高,更可能因预期费用推迟或延迟推荐治疗(27% vs 3%;P<.001),且与所有WISQOL领域较差的生活质量相关(各P<.001)。多因素logistic回归显示,女性(OR 1.81;95%CI 1.24-2.67)、医疗补助与私人保险相比(OR 3.91;95%CI 2.34-6.94)和前一年结石排出(OR 2.00;95%CI 1.41-2.86)与经济毒性独立相关。

要点

  • 约四分之一肾结石患者报告疾病特异性经济毒性(COST-11评分≤20)。
  • 经济毒性患者更可能因预期费用推迟或延迟推荐治疗(27% vs 3%;P<.001)。
  • 女性、医疗补助保险和前一年结石排出是经济毒性的独立预测因素。

核心结论

  • 约四分之一肾结石患者报告疾病特异性经济毒性;这些数据提示该疾病的经济负担可能影响决策并与较差的疾病特异性生活质量相关。

研究设计与样本

  • 对来自全国志愿者登记库(ResearchMatch)的成人肾结石患者进行横断面调查。

主要发现

  • 942份回复中,COST-11评分中位数为29(IQR 21-38),24.7%(N=233)符合疾病特异性经济毒性标准。
  • 经济毒性患者在既往一年结石治疗中自付费用高于经济负担较低患者(P<.001)。
  • 经济毒性患者更可能因预期费用推迟或延迟推荐治疗(27% vs 3%;P<.001)。
  • 结石特异性经济毒性与所有WISQOL领域较差的疾病特异性健康相关生活质量相关(各P<.001)。
  • 多因素logistic回归显示,女性(OR 1.81;95%CI 1.24-2.67)、医疗补助与私人保险相比(OR 3.91;95%CI 2.34-6.94)和前一年结石排出(OR 2.00;95%CI 1.41-2.86)与经济毒性独立相关。

关键数值与推荐

  • 经济毒性定义为COST-11评分≤20。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize stone-related financial toxicity among US adults with kidney stones through validated questionnaires for financial toxicity and disease-specific health-related quality of life. MATERIALS AND METHODS: We performed a cross-sectional survey of adults with kidney stone disease from the general population ascertained through a national registry of volunteers (ResearchMatch). A computer-based survey queried stone event history and related costs for medical care, disease-specific quality of life (WISQOL), and an 11-item measure of stone-related financial toxicity (COST-11 score). Multivariable logistic regression was performed to evaluate predictors of financial toxicity, defined as having a COST-11 score ≤20. RESULTS: Of 942 responses, median COST-11 score was 29 (IQR 21-38), and 24.7% (N = 233) met criteria for disease-specific financial toxicity. Stone-formers with financial toxicity spent more out of pocket on stone-treatment in the previous year than patients with lower financial burden (P <.001) and were more likely to defer or delay recommended treatment due to anticipated cost (27% vs 3%; P <.001). Stone-specific financial toxicity was associated with poorer disease-specific health-related quality of life across all WISQOL domains (each P <.001). Multivariable logistic regression showed that female gender (OR 1.81; 95% CI 1.24-2.67), Medicaid compared to private insurance (OR 3.91; 95% CI 2.34-6.94), and stone passage in the previous year (OR 2.00; 95% CI 1.41-2.86) were independently associated with financial toxicity. CONCLUSION: Approximately 1 in 4 individuals with kidney stone disease report disease-specific financial toxicity. These data suggest the financial burden of the condition may influence decision-making and associates with poorer disease-specific quality of life.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Cabo J, Gelikman DG, Hsi RS, et al. The Financial Burden of Nephrolithiasis and Predictors of Disease-specific Financial Toxicity. Urology. 2022. PMID: 36252733. doi:10.1016/j.urology.2022.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。